A Therapeutic Pegylated Fibroblast Growth Factor 21 Agonist/Mimetic Which Restores Leptin Responsiveness
Cirrhosis Of Liver
Bristol-Myers Squibbprotein_peptidePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
134 Active assets in the Cirrhosis Of Liver cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Veruprevir AbbVie | Phase 3 | A |
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) General Hospital of Shenyang Military Region | Phase 4 | BBB |
Tolvaptan Institute of Liver and Biliary Sciences, India | Phase 4 | BBB |
Normal Human Serum Albumin King George's Medical University | Phase 4 | BBB |
Ribavirin Peking University People's Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
A Therapeutic Pegylated Fibroblast Growth Factor 21 Agonist/Mimetic Which Restores Leptin Responsiveness is also rated in:
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative · Phase 2
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →